Literature DB >> 21624609

Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.

Lin Yang1, Martina Egger, Raffael Plattner, Helmut Klocker, Iris E Eder.   

Abstract

OBJECTIVES: To investigate why statin users display a noticeable decline in prostate specific antigen (PSA) as revealed in recent clinical trials, we tested the effects of lovastatin on the androgen signaling cascade in lymph node carcinoma of the prostate (LNCaP) prostate cancer cells.
METHODS: Effects of lovastatin alone or in combination with a small interference RNA to inhibit AR expression on cell proliferation and induction of apoptosis were assessed by [(3)H] thymidine incorporation and caspase-3 activity assay. PSA levels were measured in the cell culture supernatant by immunoassay. In addition, expression and activity of AR and Akt/protein kinase B (Akt) were determined by Western blotting and real-time polymerase chain reaction as well as by luciferase reporter gene assay.
RESULTS: Our results show that lovastatin significantly reduces AR expression and activity, resulting in decreased PSA levels. These effects were associated with inhibition of cell proliferation and induction of apoptosis. In addition, we observed that the Akt signaling pathway plays a pivotal role in lovastatin-mediated regulation of AR signaling.
CONCLUSIONS: Our data suggest that the regular use of statins may have beneficial effects in statin users by preventing prostate cancer growth through inhibition of androgen activation and expression, resulting in diminished PSA levels.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624609     DOI: 10.1016/j.urology.2010.12.074

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.

Authors:  Arla Vettenranta; Teemu J Murtola; Jani Raitanen; Paavo Raittinen; Kirsi Talala; Kimmo Taari; Ulf-Håkan Stenman; Teuvo L J Tammela; Anssi Auvinen
Journal:  JAMA Oncol       Date:  2022-01-01       Impact factor: 31.777

2.  Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).

Authors:  Yifan Kong; Lijun Cheng; Fengyi Mao; Zhuangzhuang Zhang; Yanquan Zhang; Elia Farah; Jacob Bosler; Yunfeng Bai; Nihal Ahmad; Shihuan Kuang; Lang Li; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2018-08-08       Impact factor: 5.157

3.  Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.

Authors:  Akram Mirzaei; Sina Rashedi; Mohammad Reza Akbari; Fatemeh Khatami; Seyed Mohammad Kazem Aghamir
Journal:  J Cell Mol Med       Date:  2022-04-02       Impact factor: 5.295

4.  Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?

Authors:  Sean Harrison; Kate Tilling; Emma L Turner; J Athene Lane; Andrew Simpkin; Michael Davis; Jenny Donovan; Freddie C Hamdy; David E Neal; Richard M Martin
Journal:  Cancer Causes Control       Date:  2016-11-09       Impact factor: 2.506

5.  Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.

Authors:  Hannes Neuwirt; Jan Bouchal; Gvantsa Kharaishvili; Christian Ploner; Karin Jöhrer; Florian Pitterl; Anja Weber; Helmut Klocker; Iris E Eder
Journal:  Cell Commun Signal       Date:  2020-01-24       Impact factor: 5.712

Review 6.  Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis.

Authors:  Abdulmajeed Aydh; Reza Sari Motlagh; Mishari Alshyarba; Keiichiro Mori; Satoshi Katayama; Nico Grossmann; Pawel Rajwa; Hadi Mostafai; Ekaterina Laukhtina; Benjamin Pradere; Fahad Quhal; Frederik König; Peter Nyirady; Pierre I Karakiewicz; Martin Haydter; Shahrokh F Shariat
Journal:  Cent European J Urol       Date:  2021-12-06

7.  Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.

Authors:  Jaeyoon Jung; Chunwoo Lee; Chanwoo Lee; Taekmin Kwon; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2015-09-02

8.  Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?

Authors:  J Caon; M Paquette; J Hamm; T Pickles
Journal:  Prostate Cancer       Date:  2014-03-03

9.  Effect of simvastatin on castration-resistant prostate cancer cells.

Authors:  Jenny Hanbi Kim; Michael E Cox; Kishor M Wasan
Journal:  Lipids Health Dis       Date:  2014-03-26       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.